Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer model.

Gomez-Roman N, McGregor F, Wheate NJ, Plumb JA.

J Ovarian Res. 2015 Sep 18;8:62. doi: 10.1186/s13048-015-0189-4.

2.

A cisplatin slow-release hydrogel drug delivery system based on a formulation of the macrocycle cucurbit[7]uril, gelatin and polyvinyl alcohol.

Oun R, Plumb JA, Wheate NJ.

J Inorg Biochem. 2014 May;134:100-5. doi: 10.1016/j.jinorgbio.2014.02.004. Epub 2014 Feb 18.

PMID:
24595010
3.

DNA-based aptamer fails as a simultaneous cancer targeting agent and drug delivery vehicle for a phenanthroline-based platinum(II) complex.

McGinely NL, Plumb JA, Wheate NJ.

J Inorg Biochem. 2013 Nov;128:124-30. doi: 10.1016/j.jinorgbio.2013.07.021. Epub 2013 Jul 19.

PMID:
23954482
4.

Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity.

Brown SD, Trotter KD, Sutcliffe OB, Plumb JA, Waddell B, Briggs NE, Wheate NJ.

Dalton Trans. 2012 Oct 7;41(37):11330-9. doi: 10.1039/c2dt31313h. Epub 2012 Aug 10.

PMID:
22886151
5.

Cucurbit[7]uril encapsulated cisplatin overcomes cisplatin resistance via a pharmacokinetic effect.

Plumb JA, Venugopal B, Oun R, Gomez-Roman N, Kawazoe Y, Venkataramanan NS, Wheate NJ.

Metallomics. 2012 Jun;4(6):561-7. doi: 10.1039/c2mt20054f. Epub 2012 May 21.

PMID:
22610518
6.

Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.

Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA, Brown R.

Oncogene. 2012 Oct 18;31(42):4567-76. doi: 10.1038/onc.2011.611. Epub 2012 Jan 16.

7.

Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin.

Kirkpatrick GJ, Plumb JA, Sutcliffe OB, Flint DJ, Wheate NJ.

J Inorg Biochem. 2011 Sep;105(9):1115-22. doi: 10.1016/j.jinorgbio.2011.05.017. Epub 2011 May 27.

PMID:
21704583
8.

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101).

Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Buhl-Jensen P, Molife R, Brown R, de Bono JS, Evans TR.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1273-9. doi: 10.1007/s00280-010-1419-5. Epub 2010 Aug 13.

PMID:
20706839
9.

Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin.

Brown SD, Nativo P, Smith JA, Stirling D, Edwards PR, Venugopal B, Flint DJ, Plumb JA, Graham D, Wheate NJ.

J Am Chem Soc. 2010 Apr 7;132(13):4678-84. doi: 10.1021/ja908117a.

10.

Evaluating the potential of polymer nanoparticles for oral delivery of paclitaxel in drug-resistant cancer.

Bhardwaj V, Plumb JA, Cassidy J, Ravi Kumar MN.

Cancer Nanotechnol. 2010;1(1-6):29-34. Epub 2010 Sep 7.

11.

Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.

Steele N, Finn P, Brown R, Plumb JA.

Br J Cancer. 2009 Mar 10;100(5):758-63. doi: 10.1038/sj.bjc.6604932.

12.

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.

Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TR, DeBono JS.

Clin Cancer Res. 2008 Feb 1;14(3):804-10. doi: 10.1158/1078-0432.CCR-07-1786.

13.

A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors.

Epping MT, Wang L, Plumb JA, Lieb M, Gronemeyer H, Brown R, Bernards R.

Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17777-82. Epub 2007 Oct 29.

14.

Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.

Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schätzlein A, Twelves C, Kaye SB, Brown R.

J Clin Oncol. 2007 Oct 10;25(29):4603-9.

PMID:
17925555
15.

Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells.

Pors K, Plumb JA, Brown R, Teesdale-Spittle P, Searcey M, Smith PJ, Patterson LH.

J Med Chem. 2005 Oct 20;48(21):6690-5.

PMID:
16220985
16.

Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies.

Gallagher WM, Bergin OE, Rafferty M, Kelly ZD, Nolan IM, Fox EJ, Culhane AC, McArdle L, Fraga MF, Hughes L, Currid CA, O'Mahony F, Byrne A, Murphy AA, Moss C, McDonnell S, Stallings RL, Plumb JA, Esteller M, Brown R, Dervan PA, Easty DJ.

Carcinogenesis. 2005 Nov;26(11):1856-67. Epub 2005 Jun 15.

PMID:
15958521
17.

Epigenetic approaches to cancer therapy.

Plumb JA, Steele N, Finn PW, Brown R.

Biochem Soc Trans. 2004 Dec;32(Pt 6):1095-7.

PMID:
15506976
18.

CpG-island methylation and epigenetic control of resistance to chemotherapy.

Teodoridis JM, Strathdee G, Plumb JA, Brown R.

Biochem Soc Trans. 2004 Dec;32(Pt 6):916-7. Review.

PMID:
15506923
19.

Demethylation of DNA by decitabine in cancer chemotherapy.

Brown R, Plumb JA.

Expert Rev Anticancer Ther. 2004 Aug;4(4):501-10. Review.

PMID:
15270655
20.

Cell sensitivity assays: the MTT assay.

Plumb JA.

Methods Mol Med. 2004;88:165-9. No abstract available.

PMID:
14634227
21.

Cell sensitivity assays: clonogenic assay.

Plumb JA.

Methods Mol Med. 2004;88:159-64. No abstract available.

PMID:
14634226
22.

Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.

Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R.

Mol Cancer Ther. 2003 Aug;2(8):721-8.

23.

Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer.

Pors K, Paniwnyk Z, Teesdale-Spittle P, Plumb JA, Willmore E, Austin CA, Patterson LH.

Mol Cancer Ther. 2003 Jul;2(7):607-10.

24.

Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.

Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, McGregor F, Evans TR, Ganly I, Knox RJ, Plumb JA, Keith WN.

Oncogene. 2003 Jan 23;22(3):370-80.

PMID:
12545158
25.

Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954.

Plumb JA, Bilsland A, Kakani R, Zhao J, Glasspool RM, Knox RJ, Evans TR, Keith WN.

Oncogene. 2001 Nov 22;20(53):7797-803.

26.

In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P.

Cancer Res. 2001 Jan 15;61(2):749-58.

27.

Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.

Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R.

Cancer Res. 2000 Nov 1;60(21):6039-44.

28.

Preliminary description of lesions in juvenile largemouth bass injected with largemouth bass virus.

Zilberg D, Grizzle JM, Plumb JA.

Dis Aquat Organ. 2000 Jan 14;39(2):143-6.

29.

Drug extrusion, 125I- efflux and the control of intracellular [Ca2+] in drug-resistant ovarian epithelial cells.

McAlroy HL, Bovell DL, Plumb JA, Thompson P, Wilson SM.

Exp Physiol. 1999 Mar;84(2):285-97.

PMID:
10226171
30.

Cell sensitivity assays : the MTT assay.

Plumb JA.

Methods Mol Med. 1999;28:25-30. doi: 10.1385/1-59259-687-8:25.

PMID:
21374024
31.

Cell sensitivity assays : clonogenic assay.

Plumb JA.

Methods Mol Med. 1999;28:17-23. doi: 10.1385/1-59259-687-8:17.

PMID:
21374023
32.

Inhibition of phospholipid signalling and proliferation of Swiss 3T3 cells by the wortmannin analogue demethoxyviridin.

Cross MJ, Hodgkin MN, Plumb JA, Brunton VG, Stewart A, MacAully G, Hill R, Kerr DJ, Workman P, Wakelam MJ.

Biochim Biophys Acta. 1997 Nov 28;1362(1):29-38.

33.

Killing of Edwardsiella ictaluri by macrophages from channel catfish immune and susceptible to enteric septicemia of catfish.

Shoemaker CA, Klesius PH, Plumb JA.

Vet Immunol Immunopathol. 1997 Sep;58(2):181-90.

PMID:
9336886
34.

Synthesis and anti-cancer activity of 2,6-disubstituted N-methylpiperidine derivatives and their N-oxides.

Henderson ND, Plumb JA, Robins DJ, Workman P.

Anticancer Drug Des. 1996 Sep;11(6):421-38.

PMID:
8836108
35.

Are whole extracts and purified glucosinolates from cruciferous vegetables antioxidants?

Plumb GW, Lambert N, Chambers SJ, Wanigatunga S, Heaney RK, Plumb JA, Aruoma OI, Halliwell B, Miller NJ, Williamson G.

Free Radic Res. 1996 Jul;25(1):75-86.

PMID:
8814445
36.

Sensitivity of cell lines to mitomycin C.

Watts PL, Plumb JA, Courtney JM, Scott R.

Br J Urol. 1996 Mar;77(3):363-6.

PMID:
8814839
37.
38.

DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9.

Plumb JA, Gerritsen M, Workman P.

Br J Cancer. 1994 Dec;70(6):1136-43.

39.

Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines.

Plumb JA, Gerritsen M, Milroy R, Thomson P, Workman P.

Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):295-9.

PMID:
8195022
40.

Clofazimine alters the energy metabolism and inhibits the growth rate of a human lung-cancer cell line in vitro and in vivo.

Sri-Pathmanathan RM, Plumb JA, Fearon KC.

Int J Cancer. 1994 Mar 15;56(6):900-5.

PMID:
8119778
41.

Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft.

Plumb JA, Wishart GC, Setanoians A, Morrison JG, Hamilton T, Bicknell SR, Kaye SB.

Biochem Pharmacol. 1994 Jan 20;47(2):257-66.

PMID:
8304970
45.

Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo.

Wishart GC, Plumb JA, Morrison JG, Hamilton TG, Kaye SB.

Eur J Cancer. 1992;28(1):28-31.

PMID:
1567680
46.

DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas.

Walton MI, Bibby MC, Double JA, Plumb JA, Workman P.

Eur J Cancer. 1992;28A(10):1597-600.

PMID:
1389472
47.

Lack of expression of P-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients.

Milroy R, Plumb JA, Batstone P, Maclay A, Wishart GC, Hay FG, Candlish W, Adamson R, Khan MZ, Banham S, et al.

Anticancer Res. 1992 Jan-Feb;12(1):193-200.

PMID:
1348921
48.

Identification and characterisation in vitro of cells with a non-SCLC cell-like phenotype derived from a continuous SCLC cell line.

Khan MZ, Freshney RI, Murray AM, Merry S, Plumb JA, McNicol AM.

Anticancer Res. 1991 Sep-Oct;11(5):1687-95.

PMID:
1662924
49.
50.

The effect of H-ras oncogene transfection on response of mink lung epithelial cells to growth factors and cytotoxic drugs.

Kerr DI, Plumb JA, Freshney RI, Khan MZ, Spandidos DA.

Anticancer Res. 1991 May-Jun;11(3):1349-52.

PMID:
1888171

Supplemental Content

Loading ...
Support Center